QuidelOrtho (NASDAQ:QDEL) reports sales below analyst estimates in Q3 2026 earnings, stock drops 10.6%

QuidelOrtho (QDEL) reported Q3 2026 revenue of $618.9M, missing estimates by 2.5% and down 11.6% YoY. Adjusted EPS beat estimates at $0.31. Full-year revenue guidance was lowered to $2.53B. The stock dropped 10.6% post-earnings. Management cited challenges in China and a softer respiratory season but outlined cost-cutting plans.

Original reporting
Published Nov 3, 2026, 10:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 10:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
QuidelOrtho (NASDAQ:QDEL) reports sales below analyst estimates in Q3 2026 earnings, stock drops 10.6% — source image
Decision brief

The 30-second read

$QDELBearishHigh
01

Why it matters

Revenue miss and guidance cut drive negative sentiment; however, an EPS beat and cost‑cut plan may mitigate long‑term concerns.

02

Market read

The earnings surprise and guidance downgrade triggered a 10.6% drop, making the story highly relevant for short‑term traders in the healthcare diagnostics space.

03

What to watch

Potential upside from cost‑transformation initiatives and a durable installed base in labs and immunohematology.

Relevance 8/10Novelty 9/10Timing: pre‑market today

Background

QuidelOrtho is a U.S. diagnostics firm with a market cap around $962 M; its Q3 results were released on Nov 3 2026.

Company-level read

Ticker impact

$QDELBearishHigh confidence
Context

QDEL reported Q3 2026 revenue miss and lowered full-year guidance, causing a 10.6% stock drop.

Expected impact

likely further downside as investors price in weaker revenue outlook

Evidence & confidence

Revenue fell 11.6% YoY, missed estimates, and full‑year revenue guidance was cut 1.2%; EPS guidance also lowered, prompting immediate sell‑off.

Market effects

Diagnostic and lab‑testing sector may face pressure as QDEL signals weaker demand and softer respiratory season.

U.S. healthcare stocks could see modest pullback in early trading.

Limited; primarily affects U.S. listed health‑care diagnostics peers.

Counterpoint

The EPS beat and cost‑reduction program could support a rebound if guidance is revised upward later.

Key entities

  • Brian J. Blaser

    President and CEO of QuidelOrtho, quoted on cost‑transformation plan.

Related articles

$QDELMedAI 8/10

QuidelOrtho (QDEL) Q3 2026 Earnings Call Transcript

QuidelOrtho reported Q3 2026 revenue of $619M, down 12% YoY, with declines in Point of Care and China sales. Excluding China and respiratory, revenue rose 3%. The company announced a restructuring program to save $80M annually in 2027, focusing on cost cuts and business realignment. Management emphasized long-term growth strategies, including expanding the VITROS 450 and NULEXA platforms.

$QDELHighAI 8/10

QuidelOrtho Corp (QDEL) Q3 2026 Earnings Call Highlights: Revenue Falls 12% on China

QuidelOrtho Corp (QDEL) reported a 12% year-over-year revenue decline to $619 million in Q3 2026, driven by China destocking and softer respiratory testing. China revenue dropped 45% due to pricing changes and destocking, with further pressure expected. Adjusted gross margin contracted to 47.8%, and net leverage increased to 4.5 times EBITDA. The company plans cost savings and structural changes to offset headwinds and improve profitability.

$QDELMedAI 8/10

What QuidelOrtho (QDEL) Said on Its Q3 Earnings Call

QuidelOrtho (QDEL) reported Q3 revenue decline, with Point of Care down 27% YoY. Management maintained a cautious outlook. The company announced a restructuring program targeting $80M in annual savings by 2027, with $30M-$35M in one-time charges in Q4. Adjusted EBITDA was $148M, and adjusted EPS was $0.31. QDEL narrowed its full-year revenue outlook to $2.52B-$2.54B and adjusted EBITDA to $540M-$545M.

$QDELHighAI 8/10

QuidelOrtho Q3 2026 slides: profit beat masks revenue challenges

QuidelOrtho (QDEL) reported Q3 2026 earnings of $0.31 per share, beating estimates, but revenue of $618.9M missed forecasts, causing a 6.62% after-hours drop. Revenue declined 12% YoY due to China's IVD pricing guidelines, with North America down 13.3% and China down 45.5%. Management narrowed full-year guidance, citing continued China pressure and cautious respiratory demand outlook. The company announced a restructuring plan to save $80M annually from 2027.

$QDELHighAI 8/10

QuidelOrtho: Q3 Earnings Snapshot

QuidelOrtho (QDEL) reported a Q3 loss of $53.8M, or 78 cents per share, with adjusted earnings of 31 cents per share. Revenue was $618.9M. The company expects full-year earnings of 65-70 cents per share and revenue of $2.52B-$2.54B, according to its Tuesday report.